Phys Vivas · dermatological
Skin Signs OF Internal Malignancy — Viva Defence
DCE viva defence for Skin Signs OF Internal Malignancy.
On this page & tools
Target exams
Skin Signs OF Internal Malignancy Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Skin Signs OF Internal Malignancy. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
Short case
Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]
References
- [1]Alsheyyab J, Al-Mahasneh HA, Al-Khalaileh SY, Hasan HA, et al. Pancreatic Adenocarcinoma Presented as Paraneoplastic Dermatomyositis Complicated with Rhabdomyolysis: Case Report and Review Am J Case Rep, 2026.PMID 42397795
- [2]Sadam Zeb M, Mian UU, Khan K, Gulalay A, et al. Hidden in Plain Sight: Systemic Mastocytosis Manifesting as Isolated Hepatosplenomegaly in the Absence of Cutaneous and Classical Manifestations-A Case Report and Literature Review Clin Case Rep, 2026.PMID 42368359
- [3]Raguraman V, Mysinger M, Verma M, Mohiyuddin S, et al. Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease Front Immunol, 2026.PMID 42367798
- [4]Expert Panel on Systemic Oncology, Mejias C, Morgan RL, Arora SS, et al. ACR Appropriateness Criteria® Staging and Follow-Up of Melanoma J Am Coll Radiol, 2026.PMID 41823939
- [5]Takai T, Kadono T, Fujimoto N, Yoden E, et al. Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Squamous Cell Carcinoma 2025 J Dermatol, 2026.PMID 41368724
- [6]van de Berg DJ, Vriens MR, van Santen HM, Seur A, et al. Core Outcome Set of the Surgical Treatment of Differentiated Thyroid Carcinoma: International Consensus by Delphi Study Thyroid, 2025.PMID 41203254
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922